Terence Flynn
Stock Analyst at Morgan Stanley
Total Price Targets
54
Stocks Covered
16
Sectors
Healthcare
Most Recent
Apr 10, 2026
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by Terence Flynn
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| UTHR | United Therapeutics Corporation | $519.00 | $571.24 | -9.1% | 2 | Apr 10, 2026 |
| AMGN | Amgen Inc. | $326.00 | $328.69 | -0.8% | 4 | Apr 10, 2026 |
| RPRX | Royalty Pharma plc | $63.00 | $49.41 | +27.5% | 4 | Apr 10, 2026 |
| PFE | Pfizer Inc. | $27.00 | $26.38 | +2.4% | 2 | Mar 17, 2026 |
| LLY | Eli Lilly and Company | $1313.00 | $961.67 | +36.5% | 7 | Mar 5, 2026 |
| VRTX | Vertex Pharmaceuticals Incorporated | $570.00 | $425.06 | +34.1% | 3 | Feb 13, 2026 |
| BIIB | Biogen Inc. | $190.00 | $186.69 | +1.8% | 4 | Feb 8, 2026 |
| BMY | Bristol-Myers Squibb Company | $40.00 | $58.22 | -31.3% | 2 | Feb 6, 2026 |
| REGN | Regeneron Pharmaceuticals, Inc. | $769.00 | $703.72 | +9.3% | 5 | Feb 1, 2026 |
| JNJ | Johnson & Johnson | $200.00 | $227.97 | -12.3% | 4 | Jan 22, 2026 |
| MRK | Merck & Co., Inc. | $100.00 | $111.89 | -10.6% | 4 | Nov 3, 2025 |
| GILD | Gilead Sciences, Inc. | $147.00 | $132.04 | +11.3% | 6 | Oct 31, 2025 |
| NRIX | Nurix Therapeutics, Inc. | $16.00 | $16.83 | -4.9% | 2 | Jul 15, 2025 |
| OGN | Organon & Co. | $10.00 | $13.29 | -24.7% | 1 | May 5, 2025 |
| BHVN | Biohaven Ltd. | $58.00 | $9.71 | +497.3% | 1 | Jul 24, 2024 |
| ABBV | AbbVie Inc. | $191.00 | $206.29 | -7.4% | 3 | Jul 14, 2022 |
Recent Activity
- Apr 10, 2026— Set$63.00price target onRPRX(Royalty Pharma plc)
- Apr 10, 2026— Set$519.00price target onUTHR(United Therapeutics Corporation)
- Apr 10, 2026— Set$326.00price target onAMGN(Amgen Inc.)
- Mar 17, 2026— Set$27.00price target onPFE(Pfizer Inc.)
- Mar 5, 2026— Set$1313.00price target onLLY(Eli Lilly and Company)
- Feb 13, 2026— Set$570.00price target onVRTX(Vertex Pharmaceuticals Incorporated)
- Feb 12, 2026— Set$61.00price target onRPRX(Royalty Pharma plc)
- Feb 8, 2026— Set$190.00price target onBIIB(Biogen Inc.)
- Feb 6, 2026— Set$40.00price target onBMY(Bristol-Myers Squibb Company)
- Feb 1, 2026— Set$769.00price target onREGN(Regeneron Pharmaceuticals, Inc.)
- Jan 22, 2026— Set$200.00price target onJNJ(Johnson & Johnson)
- Dec 12, 2025— Set$768.00price target onREGN(Regeneron Pharmaceuticals, Inc.)
- Dec 12, 2025— Set$156.00price target onBIIB(Biogen Inc.)
- Dec 3, 2025— Set$516.00price target onVRTX(Vertex Pharmaceuticals Incorporated)
- Nov 24, 2025— Set$1290.00price target onLLY(Eli Lilly and Company)
- Nov 3, 2025— Set$100.00price target onMRK(Merck & Co., Inc.)
- Oct 31, 2025— Set$147.00price target onGILD(Gilead Sciences, Inc.)
- Oct 15, 2025— Set$190.00price target onJNJ(Johnson & Johnson)
- Oct 10, 2025— Set$435.00price target onUTHR(United Therapeutics Corporation)
- Aug 8, 2025— Set$143.00price target onGILD(Gilead Sciences, Inc.)
Frequently Asked Questions
Who is Terence Flynn?
Terence Flynn is a stock analyst at Morgan Stanley covering 16 stocks primarily in Healthcare. They have issued 54 price targets since Apr 6, 2022.
What stocks does Terence Flynn cover?
Terence Flynn currently covers 16 stocks, including LLY, GILD, REGN, AMGN, RPRX.
What is Terence Flynn's latest price target?
Terence Flynn's most recent price target was $63.00 on RPRX (Royalty Pharma plc), set on Apr 10, 2026.
What is Terence Flynn's highest price target?
Terence Flynn's highest issued price target is $1313.00 on LLY, set on Mar 5, 2026.
More Analysts at Morgan Stanley
Coverage based on publicly published price targets. Not investment advice.